Protocol Ledger

NCT04437368 · Phase II · TERMINATED

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Interventional Phase II clinical trial protocol NCT04437368 sponsored by Novartis in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-04-26 Enrollment: 98 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04437368
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)98 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04437368
Protocol FieldVerified Registry Value
NCT IdentifierNCT04437368
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment98 participants (ACTUAL)
Registered Start Date2019-04-26
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04437368
Hospital Research SiteLocationSite Profile
Stanford Health Care and Stanford Cancer InstituteStanford, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI